NIR-PIT targeting epidermal growth factor receptor (EGFR) with cetuximab sarotalocan (cetuximab-IR700 conjugate, Akalux, Rakuten Medical Inc.)and a laser system (BioBlade, Rakuten Medical Inc.)has been used for treating patients with inoperable head and neck cancer in Japan since 2021, based on the results of clinical trials2,3. This evidence concerns the gene EGFR and head and neck cancer.